Tucatinib

Drug Profile

Tucatinib

Alternative Names: ARRY-380; Irbinitinib; ONT-380

Latest Information Update: 29 Mar 2017

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Cascadian Therapeutics; Dana-Farber Cancer Institute
  • Class 2 ring heterocyclic compounds; Antineoplastics; Diamines; Furans; Pyridines; Quinazolinones; Small molecules; Triazoles
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Solid tumours
  • Phase Unknown Colorectal cancer

Most Recent Events

  • 09 Mar 2017 Array BioPharma has patents pending for the composition of matter for tucatinib in Brazil, China, Egypt, India, Israel, Norway and Russia (Cascadian Therapeutics Form 10-K, March 2017)
  • 09 Mar 2017 Array BioPharma has patent protection for the composition of matter for tucatinib in Australia, Canada, China, Columbia, Europe, Hong Kong, Indonesia, Israel, Japan, South Korea, Mexico, Philippines, Russia, Singapore and South Africa (Cascadian Therapeutics Form 10-K, March 2017)
  • 21 Feb 2017 University of Colorado plans a phase I/II trial for Breast cancer (Combination therapy, Metastatic disease, Inoperable/Unresectable) in USA (NCT03054363)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top